Allogene Therapeutics, a California-based clinical stage immuno-oncology firm, has made remarkable strides in developing and marketing genetically engineered allogeneic T cell therapies for cancer treatment. Recently, the company has been focused on developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, for treating both pediatric and adult patients with R/R CD19 positive B-cell ALL. Allogene is also developing several other promising drugs in its portfolio, including anti-CD19 allogeneic CAR T cell product candidate, ALLO-501, which is currently in Phase I clinical trial for R/R non-Hodgkin lymphoma, and ALLO-715, an allogeneic CAR T cell product candidate, which is in Phase I clinical trial for treating R/R multiple myeloma. The company also has several other drug candidates in varying stages of development for treating other cancers, including small cell lung cancer and gastric and pancreatic cancer. With strategic collaboration agreements with The University of Texas MD Anderson Cancer Center and several other notable players in the field, Allogene is well-positioned to continue its innovative oncology research and deliver novel cancer therapies.
Allogene Therapeutics's ticker is ALLO
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 201-500 employees working at Allogene Therapeutics
It is allogene.com/about-us
Allogene Therapeutics is in the Healthcare sector
Allogene Therapeutics is in the Biotechnology industry
The following five companies are Allogene Therapeutics's industry peers: